Can the Xpert MRSA/SA BC assay be used as an antimicrobial stewardship tool? A prospective assay validation and descriptive impact assessment study in a South African setting

Table 3 Antibiotic progression in patients with Staphylococcus aureus bloodstream infection with antibiotic history (n = 45)

	Methicillin-sensitive S. aureus (n = 34)			Methicillin-resistant S. aureus (n = 11)
	Empiric Choice n (%) [95% CI]	In response to Gram result n (%) [95% CI]	On culture result n (%) [95% CI]	Empiric choice n (%) [95% CI]	In response to Gram result n (%) [95% CI]	On culture result n (%) [95% CI]
Patients receiving an agent with activity against the organism isolated^a	27 (79.4) [61.6–90.7]	29 (85.3) [68.2–94.5]	34 (100) [87.4–100]	3 (27.3) [7.3–60.7%]	5 (45.5) [18.1–75.4]	11 (100.0) [67.9–100.0]

MRSA Methicillin-resistant Staphylococcus aureus, MSSA Methicillin-sensitive Staphylococcus aureus, CI Confidence interval
^aEmpiric cover for MSSA included any agent with anti-MSSA activity, including ceftriaxone/cefotaxime for MSSA. Empiric cover for MRSA consisted of vancomycin in our setting

ISSN: 1471-2334